Is TMC's Cangrelor A CHAMPION After All?"Noise On The Line" Confounded Endpoint Data, CEO Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inability to pinpoint whether angioplasty patients enrolled in Phase III trials of The Medicines Company’s reversible antithrombotic cangrelor were already having a heart attack when they were randomized into the studies may have confounded endpoints in the failed program, according to CEO Clive Meanwell.